1. Home
  2. ELUT vs NRSN Comparison

ELUT vs NRSN Comparison

Compare ELUT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$1.15

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.83

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELUT
NRSN
Founded
2015
2017
Country
United States
Israel
Employees
N/A
15
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
29.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ELUT
NRSN
Price
$1.15
$0.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$14.00
AVG Volume (30 Days)
165.1K
148.9K
Earning Date
04-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
10.14
N/A
EPS
N/A
N/A
Revenue
$24,375,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.68
52 Week High
$3.46
$2.60

Technical Indicators

Market Signals
Indicator
ELUT
NRSN
Relative Strength Index (RSI) 63.36 44.80
Support Level $0.86 $0.85
Resistance Level $2.05 $1.30
Average True Range (ATR) 0.12 0.07
MACD 0.00 -0.01
Stochastic Oscillator 70.17 22.27

Price Performance

Historical Comparison
ELUT
NRSN

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: